8.49 USD
▲+0.21+1.92%
盘后 8.49 +1.92%
2026-08-03
市值
$444.48M
市盈率
—
EPS
-2.81
股息率
—
52 周区间
6.70 – 11.80
成交量
329.91K
Beta
-0.31
目标价
21.40
52W 低 6.7052W 高 11.80
价格走势
公司简介
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson’s disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau a...